Do analysts rate STVN or ALMR?

Alamar Biosciences has a consensus price target of $31.80, indicating a potential upside of 31.19%. Given Alamar Biosciences' higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.75 Alamar Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media prefer STVN or ALMR?

In the previous week, Alamar Biosciences had 2 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Alamar Biosciences and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.47 beat Alamar Biosciences' score of 0.41 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ALMR or SHC?

In the previous week, Alamar Biosciences had 4 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.96 beat Alamar Biosciences' score of 0.41 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sotera Health 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADPT or ALMR?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Alamar Biosciences. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 8 mentions for Alamar Biosciences. Adaptive Biotechnologies' average media sentiment score of 0.41 beat Alamar Biosciences' score of 0.41 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ALMR or FTRE?

In the previous week, Alamar Biosciences had 1 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for Alamar Biosciences and 7 mentions for Fortrea. Alamar Biosciences' average media sentiment score of 0.41 beat Fortrea's score of 0.36 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or ALMR?

In the previous week, Alamar Biosciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.65 beat Alamar Biosciences' score of 0.41 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Alamar Biosciences (ALMR) Competitors

$23.52 -0.72 (-2.97%)

As of 04:00 PM Eastern

Compare

ALMR vs. STVN, SHC, ADPT, FTRE, and MRVI

Should you buy Alamar Biosciences stock or one of its competitors? Alamar Biosciences's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Fortrea (FTRE), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Alamar Biosciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Alamar Biosciences had 2 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Alamar Biosciences and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.47 beat Alamar Biosciences' score of 0.41 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alamar Biosciences has a consensus price target of $31.80, indicating a potential upside of 31.19%. Given Alamar Biosciences' higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Stevanato Group has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.23B	4.80	€158.21M	€0.56	34.66
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A

Stevanato Group has a net margin of 10.99% compared to Alamar Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.43% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Alamar Biosciences	N/A	N/A	N/A

Summary

Stevanato Group beats Alamar Biosciences on 10 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to Sotera Health?

Alamar Biosciences (NASDAQ:ALMR) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Sotera Health has a net margin of 13.44% compared to Alamar Biosciences' net margin of 0.00%. Sotera Health's return on equity of 40.12% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Sotera Health	13.44%	40.12%	7.55%

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sotera Health has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A
Sotera Health	$1.16B	4.45	$77.94M	$0.57	31.84

In the previous week, Alamar Biosciences had 4 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.96 beat Alamar Biosciences' score of 0.41 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sotera Health	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential upside of 31.19%. Sotera Health has a consensus price target of $21.50, indicating a potential upside of 18.46%. Given Alamar Biosciences' higher possible upside, equities research analysts clearly believe Alamar Biosciences is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sotera Health	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Sotera Health beats Alamar Biosciences on 12 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Adaptive Biotechnologies currently has a consensus target price of $29.56, indicating a potential upside of 15.61%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 31.19%. Given Alamar Biosciences' higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alamar Biosciences has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	14.73	-$59.50M	-$0.41	N/A
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A

Alamar Biosciences has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -20.73%. Alamar Biosciences' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Alamar Biosciences. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 8 mentions for Alamar Biosciences. Adaptive Biotechnologies' average media sentiment score of 0.41 beat Alamar Biosciences' score of 0.41 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Adaptive Biotechnologies beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Fortrea?

Alamar Biosciences (NASDAQ:ALMR) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Alamar Biosciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A
Fortrea	$2.72B	0.73	-$986.20M	-$0.91	N/A

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential upside of 31.19%. Fortrea has a consensus price target of $22.10, indicating a potential upside of 5.24%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Alamar Biosciences is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Fortrea	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Alamar Biosciences has a net margin of 0.00% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Alamar Biosciences had 1 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for Alamar Biosciences and 7 mentions for Fortrea. Alamar Biosciences' average media sentiment score of 0.41 beat Fortrea's score of 0.36 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alamar Biosciences beats Fortrea on 8 of the 13 factors compared between the two stocks.

How does Alamar Biosciences compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Alamar Biosciences has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.87	-$130.77M	-$0.52	N/A
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A

In the previous week, Alamar Biosciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.65 beat Alamar Biosciences' score of 0.41 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Maravai LifeSciences presently has a consensus target price of $7.38, indicating a potential upside of 4.46%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 31.19%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Alamar Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -37.07%. Alamar Biosciences' return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Alamar Biosciences	N/A	N/A	N/A

Summary

Alamar Biosciences beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

Get Alamar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMR vs. The Competition

Export

Metric	Alamar Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.68B	$10.59B	$7.27B	$13.21B
Dividend Yield	N/A	1.45%	2.52%	22.89%
P/E Ratio	N/A	16.83	177.90	18.12
Price / Sales	21.99	105.56	561.77	81.05
Price / Cash	N/A	27.42	77.16	53.04
Price / Book	N/A	6.14	10.71	6.03
Net Income	-$29.82M	$56.67B	$3.50B	$380.34M
7 Day Performance	-27.09%	-3.00%	-3.18%	-3.04%
1 Month Performance	-15.67%	5.41%	-6.61%	-5.16%
1 Year Performance	N/A	25.91%	3.69%	-2.48%

Alamar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMR Alamar Biosciences	3.3934 of 5 stars	$23.52 -3.0%	$31.80 +35.2%	N/A	$1.68B	$74.21M	N/A	222	Lockup Expiration
STVN Stevanato Group	3.3759 of 5 stars	€19.42 +1.1%	N/A	-18.6%	€5.88B	€1.34B	34.68	6,010
SHC Sotera Health	3.8388 of 5 stars	$18.06 +1.3%	$21.50 +19.0%	+18.2%	$5.15B	$1.16B	31.68	3,000
ADPT Adaptive Biotechnologies	3.3855 of 5 stars	$26.49 +1.5%	$28.94 +9.2%	+68.6%	$4.23B	$276.98M	N/A	624	Analyst Forecast
FTRE Fortrea	2.6581 of 5 stars	$20.84 +2.3%	$22.10 +6.0%	+116.9%	$1.98B	$2.72B	N/A	14,300	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMR) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alamar Biosciences (ALMR) Competitors

ALMR vs. STVN, SHC, ADPT, FTRE, and MRVI

How does Alamar Biosciences compare to Stevanato Group?

Summary

How does Alamar Biosciences compare to Sotera Health?

Summary

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Summary

How does Alamar Biosciences compare to Fortrea?

Summary

How does Alamar Biosciences compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alamar Biosciences (ALMR) Competitors

ALMR vs. STVN, SHC, ADPT, FTRE, and MRVI

How does Alamar Biosciences compare to Stevanato Group?

Does the media prefer STVN or ALMR?

Do analysts rate STVN or ALMR?

Which has stronger earnings & valuation, STVN or ALMR?

Is STVN or ALMR more profitable?

Summary

How does Alamar Biosciences compare to Sotera Health?

Is ALMR or SHC more profitable?

Do institutionals and insiders have more ownership in ALMR or SHC?

Which has preferable earnings & valuation, ALMR or SHC?

Does the media refer more to ALMR or SHC?

Do analysts prefer ALMR or SHC?

Summary

How does Alamar Biosciences compare to Adaptive Biotechnologies?

Do analysts rate ADPT or ALMR?

Do institutionals & insiders have more ownership in ADPT or ALMR?

Which has preferable valuation and earnings, ADPT or ALMR?

Is ADPT or ALMR more profitable?

Does the media favor ADPT or ALMR?

Summary

How does Alamar Biosciences compare to Fortrea?

Which has better valuation and earnings, ALMR or FTRE?

Do analysts prefer ALMR or FTRE?

Is ALMR or FTRE more profitable?

Does the media prefer ALMR or FTRE?

Summary

How does Alamar Biosciences compare to Maravai LifeSciences?

Which has stronger valuation & earnings, MRVI or ALMR?

Does the media prefer MRVI or ALMR?

Do institutionals & insiders believe in MRVI or ALMR?

Do analysts recommend MRVI or ALMR?

Is MRVI or ALMR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools